Cargando…
The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules
During 2019, the US Food and Drug Administration (FDA) approved 48 new drugs (38 New Chemical Entities and 10 Biologics). Although this figure is slightly lower than that registered in 2018 (59 divided between 42 New Chemical Entities and 17 Biologics), a year that broke a record with respect to new...
Autores principales: | de la Torre, Beatriz G., Albericio, Fernando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037960/ https://www.ncbi.nlm.nih.gov/pubmed/32050446 http://dx.doi.org/10.3390/molecules25030745 |
Ejemplares similares
-
The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2018) -
The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: G. de la Torre, Beatriz, et al.
Publicado: (2019) -
The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2021) -
The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2022) -
The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules
por: de la Torre, Beatriz G., et al.
Publicado: (2023)